



This is a repository copy of *6589 Antisense oligonucleotides for reducing ACTH secretion in a model of Cushing's disease*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/218070/>

Version: Published Version

Proceedings Paper:

Varughese, M.S., Eltumi, H., Kemp, E.H. et al. (1 more author) (2024) 6589 Antisense oligonucleotides for reducing ACTH secretion in a model of Cushing's disease. In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society

<https://doi.org/10.1210/jendso/bvae163.1135>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Abstract citation ID: bvae163.1135

Neuroendocrinology and Pituitary 6589

Antisense Oligonucleotides for Reducing ACTH Secretion in a Model of Cushing's Disease

Maria Susan Varughese, Hanan Eltumi, PhD,
Elizabeth Helen Kemp, PhD,
and John D. C. Newell-Price, MD, PhD, FRCP
University of Sheffield, Sheffield, United Kingdom

Disclosure: M.S. Varughese: None. H. Eltumi: None. E.H. Kemp: None. J.D. Newell-Price: None.

Antisense Oligonucleotides for Reducing ACTH Secretion in a Model of Cushing's Disease

Background: Cushing's disease (CD) is a multi-system disorder with high morbidity and mortality characterised by pathologically raised serum cortisol due excess expression of proopiomelanocortin (*Pomc*) and overproduction of ACTH by a pituitary corticotroph adenoma. Trans-sphenoidal adenomectomy is the treatment of choice, but there is a 30% recurrence rate over time. Advances in medical therapy are needed. Antisense oligonucleotides (ASOs) can silence mRNA translation by specific base-pairing. Locked nucleic acid (LNA) and 2'-O-methyl (OMe) ribose terminals make ASOs more effective by improving affinity and resistance to nuclease degradation. **Aims:** To investigate the effectiveness of LNA- and OMe-modified anti-*Pomc* ASOs at reducing ACTH secretion from murine adrenotropic tumour (AtT20) cells. To analyse the nuclease resistance of *Pomc* ASOs and their ability to drive an immune response. **Methods:** Two ASOs (ASO2 and ASO3) were designed against *Pomc* with phosphorothioate backbones modified with either LNA or OMe ribose terminals. These were used in lipofectamine-mediated cell transfections of AtT20 cells and ACTH in the culture medium measured by immunoassay. ASO stability was assessed by nuclease degradation assays and immunogenicity by cytokine ELISAs. **Results:** When compared with untreated

AtT20 cells, LNA- and OMe-modified *Pomc* ASOs at 1 nM significantly suppressed ACTH secretion for up to 120 h and 96 h, respectively ($n = 4$; Unpaired t tests, all P values < 0.05). In contrast, control treatments, including scrambled and mismatched ASOs, did not cause a significant reduction. For comparison, 1 nM of ASO2-OMe, ASO2-LNA, ASO3-OMe and ASO3-LNA lowered ACTH at 24 h by 62%, 71%, 63% and 79%, respectively. Modified *Pomc* ASOs showed 14-31% degradation over a 120-min incubation period with 3'- and 5'-exonucleases, whilst equivalent unmodified *Pomc* ASOs were completely degraded. No secretion of IFN- α , IFN- β , TNF- α , IL-6 or IL-1 β was detected following transfection of AtT20 cells with *Pomc* ASOs. **Conclusions:** *Pomc* ASOs caused significant reduction of ACTH secretion from AtT-20 cells. LNA-modified *Pomc* ASOs were more effective than those with OMe modifications, with neither stimulating a detectable immune response. These ASOs hold promise as a systemic therapy for Cushing's disease.

Presentation: 6/3/2024